Biotech Distilled

UPDATE: Compass Pathways (CMPS) - The Accounting Trap Net Loss and the 7,300-Center Flex

Biotech Distilled's avatar
Biotech Distilled
Mar 28, 2026
∙ Paid

Biotech Distilled is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Executive Summary

This week, Compass Pathways dropped its Q4 and Full-Year 2025 financials. The underlying business operations are remarkably stable, and more importantly, management used this earnings release to directly attack the biggest remaining bear thesis in my original deep dive: the commercial logistics of the Therapist Tax. Furthermore, the dangerous debt covenant flagged back in January has been masterfully neutralized.

Bottom Line: The headline net loss is an accounting quirk, operating burn is flat, the debt trap is gone, and the commercial infrastructure strategy is finally crystalizing.

User's avatar

Continue reading this post for free, courtesy of Biotech Distilled.

Or purchase a paid subscription.
© 2026 Biotech Distilled · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture